Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
The average weight loss among those taking the new drug was 15.7% after 68 weeks, compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of ...
Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...
Recent figures suggest that more than half a million people are taking either Mounjaro or Wegovy (the version ... advice often given to women over 50 using weight-loss jabs. We need to move ...
Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing ...
Fortunes are being blown on injectable hopes of a slimmer future but a simpler and cheaper alternative could actually be in ...
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results